The failure of torcetrapib: was it the molecule or the mechanism?

Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):257-60. doi: 10.1161/01.ATV.0000256728.60226.77.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Angina Pectoris / etiology
  • Animals
  • Anticholesteremic Agents / adverse effects*
  • Anticholesteremic Agents / therapeutic use*
  • Atorvastatin
  • Cardiac Output, Low / etiology
  • Cardiovascular Diseases / prevention & control*
  • Cholesterol Ester Transfer Proteins / antagonists & inhibitors
  • Cholesterol, HDL / metabolism
  • Drug Therapy, Combination
  • Heptanoic Acids / adverse effects
  • Heptanoic Acids / therapeutic use
  • Humans
  • Mice
  • Myocardial Revascularization
  • Pyrroles / adverse effects
  • Pyrroles / therapeutic use
  • Quinolines / adverse effects*
  • Quinolines / therapeutic use*
  • Rabbits
  • Treatment Failure

Substances

  • Anticholesteremic Agents
  • CETP protein, human
  • Cholesterol Ester Transfer Proteins
  • Cholesterol, HDL
  • Heptanoic Acids
  • Pyrroles
  • Quinolines
  • torcetrapib
  • Atorvastatin